Metacrine

Focus: Metacrine is a biotechnology company focused on metabolic diseases, headquartered in San Ramon, California. The company is pre-revenue and early-stage with a focused pipeline in NASH.

Metabolic Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Metacrine

AI assessmentNot Hiring

No open roles listed right now. Follow Metacrine to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

MET409 Active

NASH

Phase 2

Clinical Trials (1)

NCT04702490Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH

Phase 2

Help build intelligence for Metacrine

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused therapeutic area (metabolic diseases/NASH) allows deep expertise development in a high-unmet-need space
Early-stage pipeline with 2 Phase 2 programs provides opportunity to influence clinical strategy and program outcomes
Ground-floor opportunity at a pre-revenue biotech with potential for significant equity upside if programs succeed

Watch Out For

No commercial revenue, no approved products, and zero active job openings signal company may be in restructuring or pause mode
Minimal public pipeline activity (only 2 Phase 2 trials) and absence of Phase 3 programs create 3-5 year timeline to potential value inflection

Generated by Claude from Metacrine's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

MET642

NASH - Nonalcoholic Steatohepatitis

Phase 2

Clinical Trials (1)

NCT04773964Study to Evaluate MET642 in Patients With NASH

Phase 2